About Orexigen Therapeutics
Orexigen Therapeutics is a publicly listed company based in San Diego (United States) founded in 2002. Developing and marketing drugs for the treatment of obesity. Orexigen Therapeutics has raised $76 million across 7 funding rounds from investors including Kleiner Perkins, Duke University and The Baupost Group. The company has 132 employees. Its focus areas include Life Sciences, Obesity and Drugs. Its legal entity is OREXIGEN THERAPEUTICS, INC. Its competitors include Altimmune, Carmot and BioAge Labs; 3 of its 3 listed competitors have raised funding.
Company details
Orexigen Therapeutics was founded in 2002 and is headquartered in San Diego, United States. The company operates in the pharmaceutical sector, with a focus on obesity management. Its primary product, Contrave (naltrexone HCl and bupropion HCl extended release), received approval in the US in September 2014. In Europe, the same drug is marketed as Mysimba (naltrexone HClbupropion HCl prolonged release). Operations center on drug development and commercialization for obesity-related conditions.
- Headquarters San Diego, United States
- Employees 132
- Stage Public
- SectorsHealthcare
- Website orexigen.com
- Social LinkedIn
- Legal Name Orexigen Therapeutics, Inc
- Total Equity Funding$76M (USD)
in 7 rounds
- Latest Funding Round$49.6M (USD), Post-IPO
Feb 2017
- InvestorsKleiner Perkins
& 8 more
- Employee Count132
Funding Insights of Orexigen Therapeutics
Orexigen Therapeutics has successfully raised a total of $76M across 7 strategic funding rounds. The most recent funding activity was a Post-IPO round of $49.6 million completed in February 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $76M
- Total Rounds 7
- Last Round Post-IPO — $49.6M
- First Round $11M
(Jan 2004)
- Investors Count 9
All 7 funding rounds of Orexigen Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2017 | $49.6M | Post-IPO | – | – | – |
| Mar 2016 | $165M | Post-IPO | – | – | – |
| Sep 2015 | $60M | Post-IPO | – | – | |
| Jun 2013 | Post-IPO | – | – | ||
| Nov 2006 | $30M | Series C | – | – | |
| Apr 2005 | $35M | Series B | – | – | |
| Jan 2004 | $11M | Series A | – | – |
9 investors in total: 9 institutional.
Investors in Orexigen Therapeutics
Orexigen Therapeutics has secured backing from 9 investors, including institutional and venture fund investors. Prominent investors backing the company include Kleiner Perkins, Duke University and The Baupost Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital investments are offered to startups by NEA. | nea.com | Menlo Park, United States | ||
Life science & tech focused VC firm investing in the US | domainvc.com | Princeton, United States | ||
Growth capital investments are made in healthcare and fintech companies. | mepvc.com | San Francisco, United States | ||
Venture capital and private equity investment firm | morgenthaler.com | Portola Valley, United States | ||
Biotech funding, drug development support, and investment in life sciences. | sofinnova.com | |||
Venture capital firm investing in early-stage tech startups | 1972 | kleinerperkins.com | Menlo Park, United States | |
Conducts long-term value-oriented investments for families, foundations, and institutions. | 1982 | baupost.com | Boston, United States | |
Operates as a funds investment management firm providing advisory services. | 1975 | wasatchfunds.com | Salt Lake City, United States | |
Multiple courses and degrees across diversified streams are offered. | 1838 | duke.edu | United States |
Investor details for Orexigen Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Orexigen Therapeutics
4 dated milestones of Orexigen Therapeutics across 15 years, from founding to its latest funding, stage changes and deals.
- Founded Orexigen Therapeutics is founded.
- Funding First funding round of $11.0M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $49.6M.
Competitors of Orexigen Therapeutics
Orexigen Therapeutics has 3 listed competitors in our database, 3 of them funded. They include Altimmune, Carmot and BioAge Labs.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| altimmune.com | 1997 | Gaithersburg, United States | $58M | 17 | Vaccines for infectious diseases and solid tumors are developed. | |
| carmot.us | 2008 | Berkeley, United States | $385.52M | Disease-modifying therapies for metabolic diseases are developed. | ||
| bioagelabs.com | 2015 | Vallejo, United States | $293.9M | 43 | Bioinformatics platform is provided for biomarkers and drug discovery. |
Detailed competitors of Orexigen Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Orexigen Therapeutics
Websites that share an audience with Orexigen Therapeutics (orexigen.com).
Websites whose visitors overlap most with Orexigen Therapeutics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| arenapharm.com | 100% | View details | |||
| medivation.com | 83% | View details | |||
| intermune.com | 83% | View details | |||
| intercell.com | 83% | View details | |||
| cepheid.com | 83% | 117.9K | #496,659 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 25 similar websites and full traffic analytics for Orexigen Therapeutics
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 25 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Obesity
3 companies that operate in the same segment as Orexigen Therapeutics (Obesity) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Satiety induction through digestable gastric balloon introduced via a swallowed capsule | 2009 | Wellesley, Massachusetts, United States | USD 174.04 M | USD 32.11 M | 137 | |
Bioinformatics platform is provided for biomarkers and drug discovery. | 2015 | Vallejo, California, United States | USD 293.9 M | USD 8.99 M | 64 | |
Disease-modifying therapies for metabolic diseases are developed. | 2008 | Berkeley, California, United States | USD 385.52 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Orexigen Therapeutics
Complete news archive for Orexigen Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Orexigen Therapeutics
Orexigen Therapeutics was founded in 2002 and raised its 1st funding round 2 years after it was founded.
Orexigen Therapeutics is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Orexigen Therapeutics is a funded company, having raised a total of $76M across 7 funding rounds to date. The company's 1st funding round was a Series A of $11M, raised on Jan 2004.
Orexigen Therapeutics has 132 employees.
Orexigen Therapeutics was founded in 2002 and is headquartered in San Diego, United States. The company operates in the pharmaceutical sector, with a focus on obesity management. Its primary product, Contrave (naltrexone HCl and bupropion HCl extended release), received approval in the US in September 2014. In Europe, the same drug is marketed as Mysimba (naltrexone HClbupropion HCl prolonged release). Operations center on drug development and commercialization for obesity-related conditions.
Orexigen Therapeutics's top competitors include BioAge Labs, Carmot and Altimmune.
Orexigen Therapeutics has 9 investors. Key investors include Kleiner Perkins, Duke University, The Baupost Group, NEA, and Wasatch Advisors.
Orexigen Therapeutics operates through Orexigen Therapeutics, Inc.